GlassScriptPhysician profile
Luwei Tao
NPI 1639601966
$3,153.49
in general payments reported to CMS, 2019-2025
39 companies · $2,773 in 2025
The $2,773 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.78 · 2021: $74.33 · 2023: $15.33 · 2024: $275 · 2025: $2,773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,063.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $352.49 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $293.73 | 2021-2025 | |
| Amgen INC. | $170.01 | 2025 | Repatha, Evenity, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $169.93 | 2024-2025 | Xifaxan |
| Radius Health, INC. | $158.50 | 2025 | Tymlos |
| Aimmune Therapeutics, INC. | $156.19 | 2025 | Zenpep |
| Pfizer INC. | $140.51 | 2025 | |
| Gilead Sciences, INC. | $135.56 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $132.87 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Ucb, INC. | $121.38 | 2024-2025 | Briviact, Nayzilam, Rystiggo |
| Otsuka America Pharmaceutical, INC. | $118.03 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $113.14 | 2023-2025 | Cologuard Collection Kit |
| Ibsa Pharma INC. | $107.09 | 2025 | Licart, Tirosint, Flector |
| Axsome Therapeutics, INC. | $106.04 | 2025 | Symbravo, Auvelity |
| Insulet Corporation | $95.32 | 2024-2025 | Omnipod |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $93.75 | 2024-2025 | |
| Lilly USA, LLC | $72.04 | 2024-2025 | Kisunla, Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $67.76 | 2024-2025 | Arexvy, Shingrix |
| Dexcom, INC. | $49.08 | 2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.75 | 2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $40.36 | 2025 | |
| Merck Sharp & Dohme LLC | $34.85 | 2021-2025 | Capvaxive, Gardasil 9 |
| Janssen Pharmaceuticals, INC | $32.85 | 2021 | |
| Vanda Pharmaceuticals INC. | $30.86 | 2025 | Ponvory |
| Lundbeck LLC | $29.34 | 2025 | Vyepti |
| Bayer Healthcare Pharmaceuticals INC. | $27.84 | 2025 | |
| Biogen, INC. | $23.95 | 2025 | Tysabri, Vumerity |
| Corcept Therapeutics | $22.66 | 2025 | Korlym |
| Alvogen INC | $21.61 | 2025 | Teriparatide |
| Beta Bionics, INC. | $21.24 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Avvisto Therapeutics, LLC | $20.98 | 2025 | Cycloset |
| Kyowa Kirin, INC. | $20.33 | 2025 | |
| Optinose US, INC. | $20.09 | 2025 | |
| Azurity Pharmaceuticals, INC. | $18.95 | 2025 | Azmiro |
| Cequr Corporation | $18.73 | 2025 | Cequr Simplicity |
| Dynavax Technologies Corporation | $18.22 | 2025 | Heplisav-B |
| Recordati_rare_diseases_inc. | $17.05 | 2025 | Isturisa |
| Allergan, INC. | $15.78 | 2020 | |
| Evoke Pharma, INC. | $15.63 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luwei Tao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.